Edition:
Deutschland

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

118.60USD
16 Feb 2018
Change (% chg)

$3.70 (+3.22%)
Prev Close
$114.90
Open
$115.40
Day's High
$119.20
Day's Low
$115.40
Volume
2,396,279
Avg. Vol
1,619,107
52-wk High
$125.84
52-wk Low
$60.81

ABBV.N

Chart for ABBV.N

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology,... (more)

Buy/Sell

Sell Hold Buy
2.41 Mean rating from 22 analysts

Overall

Beta: 1.53
Market Cap(Mil.): $144,249.59
Shares Outstanding(Mil.): 1,594.09
Dividend: 0.64
Yield (%): 2.83

US STOCKS-S&P 500 caps off strongest week in five years

* Indexes end: Dow +0.08 pct, S&P 500 +0.04 pct, Nasdaq -0.23 pct

US STOCKS-Wall Street erases gain after U.S. indicts Russians

* Indexes: Dow +0.19 pct, S&P 500 +0.16 pct, Nasdaq -0.09 pct

US STOCKS-Wall St on course for sixth day of gains

* Healthcare stocks lead gainers on S&P, Dow (Changes comment, adds details, updates prices)

BRIEF-Abbvie Announces New Phase 2 Data For Upadacitinib Showing Clinical And Endoscopic Outcomes In Crohn's Disease At 52 Weeks

* ABBVIE ANNOUNCES NEW PHASE 2 DATA FOR UPADACITINIB SHOWING CLINICAL AND ENDOSCOPIC OUTCOMES IN CROHN'S DISEASE AT 52 WEEKS

Photo

AbbVie to buy back $10 billion of shares, raises dividend

AbbVie Inc said on Thursday its board had approved a $10 billion stock repurchase program, and the drugmaker also increased its quarterly dividend, as it reaped the benefits of U.S. tax law changes.

UPDATE 1-AbbVie to buy back $10 billion of shares, raises dividend

Feb 15 AbbVie Inc said on Thursday its board had approved a $10 billion stock repurchase program, and the drugmaker also increased its quarterly dividend, as it reaped the benefits of U.S. tax law changes.

AbbVie to buy back $10 billion of shares, raises dividend

Feb 15 AbbVie Inc on Thursday said its board had approved a $10 billion stock repurchase program, and the drugmaker also increased its quarterly dividend, as it reaped benefits from changes to the U.S. tax code.

BRIEF-Abbvie Increases Dividend, Announces New Stock Repurchase Program

* ABBVIE INCREASES DIVIDEND AND ANNOUNCES NEW STOCK REPURCHASE PROGRAM

Regeneron CEO says fears over Eylea 'greatly exaggerated'

Fears of the demise of blockbuster eye drug Eylea were "greatly exaggerated," Regeneron Pharmaceuticals Inc's chief executive said on Thursday, after the treatment and new eczema drug Dupixent powered the company's fourth-quarter results.

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -0.24%
Rohstoffe -0.32%
Industrie -0.21%
Konjunktur abhängige Waren & Dienstleistungen -0.18%
Konjunktur unabhängige Waren & Dienstleistungen -0.16%
Finanzindustrie -0.08%
Pharma -0.07%
Technologie -0.19%
Telekommunikation -0.05%